Saudi Arabia approved an adalimumab biosimilar, a denosumab biosimilar entered the market in the Republic of Korea, and Dr. Reddy’s Laboratories announced the completion of a phase 3 study for its ...
A new report from HHS has revealed that if the Inflation Reduction Act (IRA) had been implemented in 2020, Medicare Part D ...
Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health in Sacramento, California, details the regulatory decisions from ...
IQVIA’s Global Use of Medicines Report for 2023 has revealed increased uptake of biosimilars around the world and predicted that biosimilars could generate nearly $300 billion in savings by 2027.
Alteogen and Alvotech announce updates for their respective license partnerships; Samsung Bioepis speeds up ...
Patent litigators from Fish & Richardson, an intellectual property law firm, regaled audiences during a webinar covering all ...
Researchers found that a denosumab biosimilar appeared comparably safe and effective to reference drug Prolia.
The China National Medical Products Administration (NMPA) approved Bio-Thera Solution’s tocilizumab biosimilar (BAT1806) ...
As part of a series of interviews, Kyung-Ah Kim, executive vice president of Samsung Bioepis, offered insight into how developers view the current biosimilars market, the relevance of ...
The United Kingdom has approved STADA Arzneimittel and Xbrane Biopharma’s Ximluci, a ranibizumab biosimilar referencing ...